Uchitsubo K, Masuda J, Akazawa T, Inoue R, Tsukada K, Gatanaga H, Terakado H, Oka S.
Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection.
Global Health & Medicine. 2(6):384-387, 2020.
Kobayashi M, Chinen M, Hirano A, Hayashida T, Watanabe K, Masuda J
Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis.
Journal of Antimicrobial Chemotherapy. 76:1370–1372, 2021.
Masuda J, Kato Y
Simultaneous Determination of Raltegravir, Dolutegravir, Elvitegravir, and Bictegravir in Human Plasma Using High-performance Liquid Chromatography-tandem Mass Spectrometry
Showa Univ J Med Sci. 32 (1), 91-102, 2020.
Yonemura T, Okada N, Sagane K, Okamiya K, Ozaki H, Iida T, Yamada H, Yagura H
Effects of Milk or Apple Juice Ingestion on the Pharmacokinetics of Elvitegravir and Cobicistat in Healthy Japanese Male Volunteers: A Randomized, Single-Dose, Three-Way Crossover Study.
Clin Pharmacol Drug Dev. 7(7):737-743, 2018.
Kato M, Togami H, Fukushima N, Kawaguchi S, Hirano A, Nakai M, Yokomaku Y
No correlation was observed between adverse events and plasma dolutegravir concentrations in dolutegravir containing regimen
3rd Asia Pacific AIDS & Co-Infections Conference, HongKong, 6.28-6.30, 2018
Yagura H, Watanabe D, Nakauchi T, Tomishima, K, Nishida Y, Yoshino M, Yamazaki K, Uehira T, Shirasaka T
Association of tenofovir level and discontinuation due to impaired renal function.
HIV Drug Therapy 2018, Glasgow, 10.29, 2018
Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A, Takahashi M, Hirota K, Ikuma M, Kasai D, Nishida Y, Yoshino M, Yamazaki K, Uehira T, Shirasaka T
Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.
BMC Infect Dis. 16;17(1):622, 2017.
学会・シンポジウム等における口頭・ポスター発表
増田純一
ART変更-耐性/ART変更-相互作用
HIV Metropolitan Pharmacist Network, 東京, 4.22, 2017
押賀充則
ACCにおける抗HIV薬の処方状況
HIV Specialty Pharmacist Conference 2017, 東京, 7.22, 2017
Togami H, Hirano A, Yokomaku Y
Correlation between UGT1A1*6 and *28 genotype, and plasma dolutegravir concentrations in Japanese HIV-1 infected patients
9th IAS conference on HIV science, France, 7.23, 2017
Kato M, Togami H, Fukushima N, Kawaguchi S, Hirano A, Matsumoto S, Yokomaku Y
Relationship between plasma dolutegravir concentration and cause of anti- HIV therapy discontinuation
APSA-ASCEPT 2017 Joint Scientific Meeting, Australia, 12.5, 2017
2016年度
学会誌・雑誌等における論文
Ikuma M, Watanabe D, Yagura H, Ashida M, Takahashi M, Shibata M, Asaoka T, Yoshino M, Uehira T, Sugiura W, Shirasaka T
Therapeutic Drug Monitoring of Anti-human Immunodeficiency Virus Drugs in a Patient with Short Bowel Syndrome.
Intern Med. 55(20):3059-3063, 2016.
学会・シンポジウム等における口頭・ポスター発表
Togami H, Kato M, Fukushima N, Hirano A, Imamura J, Hachiya A, Iwatani Y, Matsumoto S, Yokomaku Y
Treatment outcome for NRTI sparing regimen consisting of dolutegravir and rilpivirine
1st Asia Pacific AIDS & Co-Infections Conference 2016, HongKong, 5.17, 2016
Hirano A, Kato M, Fukushima N, Togami H, Imamura J, Hachiya A, Iwatani Y, Matsumoto S, Yokomaku Y
Antiretroviral combination regimens to prevent mother-to-child transmission
for Japanese HIV-1 infected patients
1st Asia Pacific AIDS & Co-Infections Conference 2016, HongKong, 5.17, 2016
Kato M, Fukushima N, Togami H, Hirano A, Matsumoto S, Yokomaku Y
Adverse reactions on the pharmacokinetics of dolutegravir in Japanese HIV-1 infected patients
1st Asia Pacific AIDS & Co-Infections Conference 2016, HongKong, 5.17, 2016
Yagura H, Watanabe D, Ashida M, Nakauchi T, Tomishima K, Togami H, Hirano A, Sako R, Doi T, Yoshino M, Takahashi M, Yamazaki K, Uehira T, Shirasaka T
Relationships between dolutegravir plasma-trough concentrations, UGT1A1 genetic polymorphisms, and side-effects of central nervous system in Japanese HIV-1-infected patients.
HIV Drug Therapy 2016, Glasgow, 10.25, 2016
Yagura H, Watanabe D, Nakauchi T, Tomishima K, Kasai D, Nishida Y, Yoshino M, Uehira T, Yamazaki K, Shirasaka T
Effect of dolutegravir plasma concentration on central nervous system side effects. Conference on Retroviruses and Opportunistic Infections 2017, Seattle, 2.15, 2017